Impact of General Factors on Glioma Immunotherapy
- Author:
Qilin HUANG
1
;
Dongmei WANG
;
Guojie YAO
;
Hongxiang WANG
Author Information
- Publication Type:REVIEW
- From:Journal of Clinical Neurology 2022;18(1):3-13
- CountryRepublic of Korea
- Language:English
- Abstract: Glioma remains the most common malignant tumor in the brain and is also the most difficult to treat. Immunotherapy achieving long-lasting tumor remission in multiple cancer types has received considerable attention due to its potential to improve the treatment outcomes of patients with glioma. However, clinical trials have not yet demonstrated major improvements in prognoses, which might be attributable to the extrinsic components and intrinsic mechanisms involved in the tumor microenvironment and immune system. It is particularly noteworthy that there is emerging evidence that current routine treatment modalities and the physical and psychological characteristics of patients have different impacts on the efficacy of glioma immunotherapy. This article addresses how these factors interact with the host immune system and tumor microenvironment, and highlights their potential roles in glioma immunotherapy, with the ultimate goal of developing better immunotherapybased personalized medicine strategies.
